Tenax Therapeutics (TENX) EPS (Weighted Average and Diluted) (2010 - 2026)
Tenax Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.35 in Q1 2026, up 7.89% quarter-over-quarter from -$0.38 in Q4 2025, and down 25.0% year-over-year from -$0.47 in Q1 2025.
Tenax Therapeutics' EPS (Weighted Average and Diluted) history runs 10 years deep, the most recent figure standing at -$0.35 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 25.0% year-over-year to -$0.35; the TTM figure through Mar 2026 stood at -$1.4 (up 32.69% YoY), while the FY2025 annual figure was -$1.34, down 16.52% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.35 for Q1 2026 at Tenax Therapeutics, up from -$0.38 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.22 in Q4 2024 to a low of -$49.42 in Q4 2023.
- A 4-year average of -$5.6 and a median of -$0.37 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 100.45% in 2024 and slumped 272.73% in 2025, its largest moves.
- Tenax Therapeutics' EPS (Weighted Average and Diluted) stood at -$49.42 in 2023, then surged by 100.45% to $0.22 in 2024, then plunged by 272.73% to -$0.38 in 2025, then advanced by 7.89% to -$0.35 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.35, -$0.38, and -$0.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | -0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.40 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -0.28 |
| Dec 31, 2024 | 0.22 |
| Sep 30, 2024 | -0.19 |
| Jun 30, 2024 | -1.83 |
| Mar 31, 2024 | -3.12 |
| Dec 31, 2023 | -49.42 |
| Jan 31, 2015 | -0.10 |
| Oct 31, 2014 | -0.14 |
| Jul 31, 2014 | -0.08 |
| Apr 30, 2014 | -0.13 |
| Jan 31, 2014 | -0.44 |
| Oct 31, 2013 | -1.25 |
| Jul 31, 2013 | -3.36 |
| Apr 30, 2013 | -0.77 |
| Jan 31, 2013 | -2.78 |
| Oct 31, 2012 | -2.63 |
| Jul 31, 2012 | -4.30 |
| Apr 30, 2012 | -13.42 |
| Jan 31, 2012 | -0.39 |
| Oct 31, 2011 | -0.29 |
| Jul 31, 2011 | -0.33 |
| Apr 30, 2011 | -0.12 |
| Jan 31, 2011 | -0.11 |
| Oct 31, 2010 | -0.09 |
| Jul 31, 2010 | -0.13 |